Platelet inhibition by P2Y12 antagonists is potentiated by adenosine signalling activators
Open Access
- 12 August 2021
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 178 (23) , 4758-4771
Abstract
Background and Purpose: P2Y12 receptor antagonists reduce platelet aggregation and the incidence of arterial thrombosis. Adenosine signalling in platelets directly affects cyclic nucleotide tone, which we have shown to have a synergistic relationship with P2Y12 inhibition. Several studies suggest that ticagrelor inhibits erythrocyte uptake of adenosine and that this could also contribute to its antiplatelet effects. We therefore examined the effects on platelet activation of adenosine signalling activators in combination with the P2Y12 receptor antagonists ticagrelor and prasugrel.Experimental Approach: Human washed platelets, platelet‐rich plasma and whole blood were used to test the interactions between ticagrelor or prasugrel and adenosine or 5′‐N‐ethylcarboxamidoadenosine (NECA). Platelet reactivity to thrombin, protease‐activated receptor 1 (PAR‐1) activation or collagen was assessed by a combination of 96‐well plate aggregometry, light transmission aggregometry, whole blood aggregometry, ATP release assay and levels of cAMP.Key Results: The inhibitory effects of ticagrelor and prasugrel on platelet aggregation and ATP release were enhanced in the presence of adenosine or NECA. Isobolographic analysis indicated a powerful synergy between P2Y12 receptor inhibition and adenosine signalling activators. Increased levels of cAMP in platelets were also observed. In all cases, ticagrelor showed similar synergistic effects on platelet inhibition as prasugrel in the presence of adenosine or NECA.Conclusion and Implications: These results indicate that P2Y12 antagonists have a synergistic relationship with adenosine signalling and that their efficacy may depend partly upon the presence of endogenous adenosine. This effect was common for prasugrel and ticagrelor despite reports of differences in their effects upon adenosine reuptake.Keywords
Funding Information
- British Heart Foundation (PG/11/75/29105, PG/12/68/29779)
- William Harvey Research Foundation
This publication has 39 references indexed in Scilit:
- Blockade of the purinergic P2Y 12 receptor greatly increases the platelet inhibitory actions of nitric oxideProceedings of the National Academy of Sciences, 2013
- Antiplatelet effects of aspirin vary with level of P2Y12 receptor blockade supplied by either ticagrelor or prasugrelJournal of Thrombosis and Haemostasis, 2011
- In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregationJournal of Thrombosis and Haemostasis, 2010
- A new role for the A2b adenosine receptor in regulating platelet functionJournal of Thrombosis and Haemostasis, 2010
- Ticagrelor binds to human P2Y12 independently from ADP but antagonizes ADP‐induced receptor signaling and platelet aggregationJournal of Thrombosis and Haemostasis, 2009
- Utility of 96-well plate aggregometry and measurement of thrombi adhesion to determine aspirin and clopidogrel effectivenessThrombosis and Haemostasis, 2009
- Aspirin resistance: position paper of the Working Group on Aspirin ResistanceJournal of Thrombosis and Haemostasis, 2005
- Role of G protein–gated inwardly rectifying potassium channels in P2Y12 receptor–mediated platelet functional responsesBlood, 2004
- Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trialThe Lancet, 2004
- A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)The Lancet, 1996